Rezolute dips 19%, prices $60M offering at $4 per share

Late-stage biopharmaceutical company Rezolute ( NASDAQ: RZLT ) priced underwritten public offering of an aggregate of 11.25M shares at $4.00 per share.

Pre-funded warrants to purchase up to 3.75M shares at an offering price of $3.999 per pre-funded warrant.

Gross proceeds are expected to be ~$60M. The closing of the offering is expected to occur on or about June 17, 2024. The stock price dipped 18.

9% on Friday during pre-market hours of trade. More on Rezolute Biggest stock movers today: ADBE, RH, and more Rezolute stock rockets 50% on Phase 2 results for eye drug RZ402 Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute.